Literature DB >> 9952386

Tuberculosis and chronic hepatitis B virus infection in Africans and variation in the vitamin D receptor gene.

R Bellamy1, C Ruwende, T Corrah, K P McAdam, M Thursz, H C Whittle, A V Hill.   

Abstract

The active metabolite of vitamin D, 1,25 dihydroxyvitamin D3, is an important immunoregulatory hormone [1]. Its effects are exerted by interaction with the vitamin D receptor, which is present on human monocytes and activated T and B lymphocytes. Variation in the vitamin D receptor gene was typed in 2015 subjects from large case-control studies of three major infectious diseases: tuberculosis, malaria, and hepatitis B virus. Homozygotes for a polymorphism at codon 352 (genotype tt) were significantly underrepresented among those with tuberculosis (chi2=6.22, 1 df, P=. 01) and persistent hepatitis B infection (chi2=6.25, 1 df, P=.01) but not in subjects with clinical malaria compared with the other genotypes. Therefore, this genetic variant, which predisposes to low bone mineral density in many populations, may confer resistance to certain infectious diseases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9952386     DOI: 10.1086/314614

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  115 in total

1.  Genetic predisposition to clinical tuberculosis: bridging the gap between simple and complex inheritance.

Authors:  L Abel; J L Casanova
Journal:  Am J Hum Genet       Date:  2000-07-05       Impact factor: 11.025

Review 2.  Factors affecting susceptibility and resistance to tuberculosis.

Authors:  P D Davies; J M Grange
Journal:  Thorax       Date:  2001-09       Impact factor: 9.139

3.  Genetic regulation of acquired immune responses to antigens of Mycobacterium tuberculosis: a study of twins in West Africa.

Authors:  A Jepson; A Fowler; W Banya; M Singh; S Bennett; H Whittle; A V Hill
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

4.  Polymorphism rs2239185 in vitamin D receptor gene is associated with severe community-acquired pneumonia of children in Chinese Han population: a case-control study.

Authors:  Wei Li; Linying Guo; Hongri Li; Chunrong Sun; Xiaodai Cui; Guowei Song; Jianhua Wang; Qi Zhang
Journal:  Eur J Pediatr       Date:  2014-11-01       Impact factor: 3.183

5.  Strong influence of human leukocyte antigen (HLA)-DP gene variants on development of persistent chronic hepatitis B virus carriers in the Han Chinese population.

Authors:  Xiuchan Guo; Yong Zhang; Ji Li; Jingchen Ma; Zuli Wei; Wenjie Tan; Stephen J O'Brien
Journal:  Hepatology       Date:  2011-01-04       Impact factor: 17.425

Review 6.  [Genetics of susceptibility and resistance to tuberculosis].

Authors:  R D Horstmann
Journal:  Internist (Berl)       Date:  2003-11       Impact factor: 0.743

7.  Susceptibility to tuberculosis--the importance of the pathogen as well as the host.

Authors:  H McShane
Journal:  Clin Exp Immunol       Date:  2003-07       Impact factor: 4.330

Review 8.  New antituberculous drugs in development.

Authors:  Umesh G Lalloo; Anish Ambaram
Journal:  Curr HIV/AIDS Rep       Date:  2010-08       Impact factor: 5.071

9.  A polymorphism in Toll-interleukin 1 receptor domain containing adaptor protein is associated with susceptibility to meningeal tuberculosis.

Authors:  Thomas R Hawn; Sarah J Dunstan; Guy E Thwaites; Cameron P Simmons; Nguyen Thuong Thuong; Nguyen Thi Ngoc Lan; Hoang Thi Quy; Tran Thi Hong Chau; Nguyen T Hieu; Stephanie Rodrigues; Marta Janer; Lue Ping Zhao; Tran Tinh Hien; Jeremy J Farrar; Alan Aderem
Journal:  J Infect Dis       Date:  2006-09-12       Impact factor: 5.226

10.  Genetic protection against hepatitis B virus conferred by CCR5Delta32: Evidence that CCR5 contributes to viral persistence.

Authors:  Chloe L Thio; Jacquie Astemborski; Arman Bashirova; Timothy Mosbruger; Spencer Greer; Mallory D Witt; James J Goedert; Margaret Hilgartner; Audrey Majeske; Stephen J O'Brien; David L Thomas; Mary Carrington
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.